Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4849 in Advanced Solid Tumors
NCT06443489Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-4849 in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events / Serious Adverse Events at 24 months and 2 more. Started Jun 2024; status: recruiting.
02
Drugs
SHR-4849
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06443489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06443489.